SCHEMBL17331809

SCHEMBL17331809

CCOC(=O)c1cc2c(F)cccn2c1-c1ccccn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.45
HPGD P15428 5/20 0.45
ALDH1A1 P00352 5/20 0.45
GAA P10253 2/20 0.45
GLA P06280 1/20 0.45
KMT2A Q03164 2/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
MEN1 O00255 1/20 0.44
JMJD6 Q6NYC1 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA4 P22748 1/20 0.43
CA9 Q16790 1/20 0.43
HTT P42858 4/20 0.43
HSD17B10 Q99714 4/20 0.43
NPSR1 Q6W5P4 2/20 0.42
IDO1 P14902 1/20 0.42
LMNA P02545 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17331949 0.82 KDM4E (0.48) KDM4EHPGDALDH1A1GAAGLA
SCHEMBL17372789 0.79 BAZ2B (0.41) KDM4EHPGDALDH1A1KMT2ANPC1
SCHEMBL17331599 0.78 KDM4E (0.49) KDM4EHPGDALDH1A1GAAGLA
SCHEMBL17331564 0.76 HTT (0.43) KDM4EHPGDALDH1A1GAAGLA
SCHEMBL17331523 0.76 KDM4E (0.47) KDM4EHPGDALDH1A1GAAGLA
SCHEMBL17331692 0.75 IDO1 (0.55) KDM4EHPGDALDH1A1GAAGLA
SCHEMBL17331910 0.74 RAB9A (0.41) KDM4EHPGDALDH1A1KMT2ANPC1
SCHEMBL17331653 0.73 IDO1 (0.51) KDM4EHPGDALDH1A1GAAGLA
SCHEMBL17331971 0.72 BAZ2B (0.40) KDM4EALDH1A1GAANPC1RAB9A
SCHEMBL17331754 0.72 BRD4 (0.39) KDM4ENPC1RAB9ANPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3157920-B1 INDOLIZINE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARM SPA (IT) 2019-08-07 EP disclosed
EP-3157920-B1 INDOLIZINE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARM SPA (IT) 2019-08-07 EP disclosed
EP-3157920-A1 INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2017-04-26 EP disclosed
US-9527869-B2 Indolizine derivatives as phoshoinositide 3-kinases inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2016-12-27 US disclosed
US-9527869-B2 Indolizine derivatives as phoshoinositide 3-kinases inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2016-12-27 US disclosed
US-9527869-B2 Indolizine derivatives as phoshoinositide 3-kinases inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2016-12-27 US disclosed
WO-2015193263-A1 INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2015-12-23 WO disclosed
WO-2015193263-A1 INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2015-12-23 WO disclosed
US-20150361100-A1 INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2015-12-17 US disclosed
US-20150361100-A1 INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2015-12-17 US disclosed
US-20150361100-A1 INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2015-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150361100-A1 INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS PIP4K2B, PIP5K1B, PIP4K2A KDM4E 3308/4885HPGD 1479/4885ALDH1A1 4722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.